1. Home
  2. CTXR vs DETX Comparison

CTXR vs DETX Comparison

Compare CTXR & DETX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Citius Pharmaceuticals Inc.

CTXR

Citius Pharmaceuticals Inc.

N/A

Current Price

$0.53

Market Cap

13.4M

Sector

Health Care

ML Signal

N/A

Logo Liberty Defense Holdings Ltd. Common Shares

DETX

Liberty Defense Holdings Ltd. Common Shares

N/A

Current Price

$1.53

Market Cap

14.8M

ML Signal

N/A

Company Overview

Basic Information
Metric
CTXR
DETX
Founded
2007
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Telecommunications Equipment
Sector
Health Care
Telecommunications
Exchange
Nasdaq
Nasdaq
Market Cap
13.4M
14.8M
IPO Year
2010
2022

Fundamental Metrics

Financial Performance
Metric
CTXR
DETX
Price
$0.53
$1.53
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 258.4K
25.4K
Earning Date
08-14-2026
11-27-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 43.38
N/A
EPS
N/A
★ N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$104.18
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.37
$1.36
52 Week High
$1.60
$4.25

Technical Indicators

Market Signals
Indicator
CTXR
DETX
Relative Strength Index (RSI) 53.77 37.26
Support Level $0.48 $1.36
Resistance Level $0.61 $2.43
Average True Range (ATR) 0.05 0.27
MACD 0.02 0.04
Stochastic Oscillator 62.85 33.63

Price Performance

Historical Comparison
CTXR
DETX

About CTXR Citius Pharmaceuticals Inc.

Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and distinct prescription products. It aims to provide therapeutic products that address unmet medical needs yet have a lower development risk than is usually associated with new chemical entities. The company's flagship product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein. It operates through a single operating and reportable segment which is focused on developing and commercializing pioneering targeted oncology therapies.

About DETX Liberty Defense Holdings Ltd. Common Shares

Liberty Defense Holdings Ltd is engaged in the development and commercialization of security detection technologies such as airports, stadiums, schools, and more. The company's Hexwave product utilizes millimeter wave technology and Advanced 3D imaging to detect concealed threats. In addition to HEXWAVE, the company has licensed High-Definition Advanced Imaging Technology (HD-AIT) for body and shoe scanning. The Company operates through three distinct segments: Corporate, HEXWAVE, and Contract. The company generates the majority of its revenue from the Contract segment. Geographically, the company generates the majority of its revenue from the United States.

Share on Social Networks: